The FDA has approved Rinvoq (upadacitinib), a Janus kinase inhibitor, for the treatment of adults with giant cell arteritis.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for milsaperidone (Bysanti™) for the treatment of acute ...

The Food and Drug Administration (FDA) has approved Atzumi ™ (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.